The earnings call reflected a positive outlook with strong revenue growth, successful product launches, and significant pipeline advancements. However, the company faces challenges in achieving profitability and navigating regulatory and market landscapes.

Company Guidance -

Q2 2025

In the Axsome Therapeutics First Quarter 2025 Conference Call, the company reported a strong performance with a 62% year-over-year increase in total revenue, attributed mainly to the demand for Auvelity and Sunosi. The recent FDA approval of Symbravo was highlighted as a significant milestone. Key pipeline priorities were discussed, including advancing three novel NDA-stage product candidates: AXS-14 for fibromyalgia, AXS-05 for Alzheimer's disease agitation, and AXS-12 for cataplexy and narcolepsy. The company successfully submitted the NDA for AXS-14 and plans to submit the sNDA for AXS-05 in the third quarter, with a potential launch in 2026. Several Phase III trials are underway, including Solriamfetol for ADHD, MDD, binge eating disorder, and excessive sleepiness related to shift work disorder. Financially, Axsome reported $121.5 million in total product revenues for the quarter, with net product sales of $120.4 million. The company ended Q1 2025 with $300.9 million in cash and cash equivalents and expressed confidence in reaching cash flow positivity with its current resources.

Significant Revenue Growth

Axsome Therapeutics reported a year-over-year total revenue growth of 62% for the first quarter of 2025, with total product revenues reaching $121.5 million.

Successful Product Launch and FDA Approval

The FDA approved Symbravo, Axsome's second internally developed product, marking a significant achievement in expanding their product portfolio.

Strong Performance of Key Products

Auvelity achieved an 80% year-over-year growth in net product sales, reaching $96.2 million in the first quarter of 2025.

Pipeline Advancements

Axsome submitted an NDA for AXS-14 for fibromyalgia and plans to submit an sNDA for AXS-05 for Alzheimer's disease agitation in the third quarter of 2025.

Expansion in Clinical Programs

Announced positive top-line results from Phase III trials for Solriamfetol in ADHD and Symbravo in migraine, paving the way for further trials and potential market expansion.

Axsome Therapeutics (AXSM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AXSM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 04, 2025	2025 (Q2)	-1.05 / -	-1.67	―	―	―
May 05, 2025	2025 (Q1)	-1.35 / -1.22	-1.44	15.28% (+0.22)
Feb 18, 2025	2024 (Q4)	-1.00 / -1.54	-2.08	25.96% (+0.54)
Nov 12, 2024	2024 (Q3)	-1.38 / -1.34	-1.32	-1.52% (-0.02)
Aug 05, 2024	2024 (Q2)	-1.31 / -1.67	-1.54	-8.44% (-0.13)	―
May 06, 2024	2024 (Q1)	-1.21 / -1.44	-0.26	-453.85% (-1.18)	―
Feb 20, 2024	2023 (Q4)	-1.17 / -2.08	-1.41	-47.52% (-0.67)
Nov 06, 2023	2023 (Q3)	-1.20 / -1.32	-1.07	-23.36% (-0.25)	―
Aug 07, 2023	2023 (Q2)	-1.21 / -1.54	-1.06	-45.28% (-0.48)	―
May 08, 2023	2023 (Q1)	-1.30 / -0.26	-1.03	74.76% (+0.77)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AXSM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2025	$112.21	$116.49	+3.81%
Feb 18, 2025	$131.15	$128.09	-2.33%
Nov 12, 2024	$90.98	$99.49	+9.35%
Aug 05, 2024	$84.42	$83.21	-1.43%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Axsome Therapeutics Inc (AXSM) report earnings?

Axsome Therapeutics Inc (AXSM) is schdueled to report earning on Aug 04, 2025, Before Open (Confirmed).

What is Axsome Therapeutics Inc (AXSM) earnings time?

Axsome Therapeutics Inc (AXSM) earnings time is at Aug 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AXSM EPS forecast?

AXSM EPS forecast for the fiscal quarter 2025 (Q2) is -1.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing